ASLAN Pharmaceuticals received a notice for failing to meet stockholders' equity requirement, has 45 days to submit a compliance plan, and can request up to 180 days extension.
Nasdaq-listed ASLAN Pharmaceuticals received a notice stating it failed to meet the stockholders' equity requirement of $2.5M due to a $13.3M deficit. ASLAN has 45 days to submit a plan for regaining compliance, and if accepted, may receive an extension of up to 180 days. Despite the notice, ASLAN's American Depositary Shares will remain listed on Nasdaq, pending compliance with other standards.
April 19, 2024
5 Articles